September, 2026 - Kan and Krishme

September 16, 2026
Blog
No Comments

Indian FSSAI’s New Labelling Rules 2026

Background The Food Safety and Standard (Labelling and Display) First Amendment Regulation, 2026 were notified by FSSAI on March 24, 2026 to amend the existing Food Safety And Standards (Labelling And Display) 2020. The Amendment aims to simplify certain labelling requirements while improving clarity and traceability. It introduces relaxations for infant nutrition products and small packages, clarifies […]

September 15, 2026
Blog
No Comments

Beyond the Model: What GenAI Patent Trends Reveal About the Future of AI Innovation

Generative Artificial Intelligence (“GenAI”) is moving beyond chatbots and large language models (“LLMs”) into multimodal systems, reasoning models, agentic AI, semiconductor infrastructure, data centres, energy systems and sector-specific applications. WIPO’s recent analysis, “Beyond the Chatbot: What Patent Data Reveals About the Next Phase of GenAI,” captures this shift through global patent activity. [1] The numbers are striking: published GenAI patent families increased […]

Well-Known Trademarks under Section 11(2)

September 7, 2026
Blog
No Comments

Well-Known Trademarks Without a Formal Declaration: Delhi High Court Clarifies the Scope of Section 11(2)

The Delhi High Court’s decision in Columbia Pictures Industries, Inc. v. Registrar of Trade Marks & Anr., C.A. (COMM. IPD-TM) 44/2025, decided on 6 July 2026, addresses an important question concerning the protection of well-known trademarks in India: whether a trademark must first be formally declared “well known” under Rule 124 of the Trade Marks […]

September 3, 2026
Blog
No Comments

Beyond the Source Code: Can India’s Patent Framework Accommodate Black-box Software?

Introduction The rapid growth of Artificial Intelligence (AI), machine learning, and data-driven technologies has increased the significance of “black box” software systems. A black box algorithm is generally understood as a computational model where the inputs and outputs are known, but the internal decision-making process is either opaque or not readily understandable. While such technologies have […]

September 2, 2026
Blog
No Comments

Array Biopharma v. Controller of Patents: Delhi HC on Combination Drug Patents

The Delhi High Court’s decision in Array Biopharma Inc. v. Deputy Controller of Patents and Designs [C.A.(COMM.IPD-PAT) 37/2023] provides significant guidance on inventive step, the exclusions under Sections 3(d) and Section 3(i) of the Patent Act, and the standard of reasoning expected from the Patent Office when refusing combination patents involving multiple independently known active […]